Therefore, major international guidelines recommend ACE inhibitors or ARBs as foundational therapy, particularly in patients with CKD and albuminuria, to delay disease progression and improve long-term renal outcomes (30, 31, 69, 70). Here, ACE is linked to chronic kidney disease.